Applying data science and enhanced AI to improve decision-making in healthcare
Precision Medicine is nothing less than the largest paradigm shift in medicine ever. The advent and ever-growing understanding of molecular information is the newest and the richest dimension in medicine. In combination with novel artificial intelligence and machine learning (AI/ML) technologies it creates a totally new approach for prognostic and predictive in silico science that can guide some of the most promising yet most challenging domains of precision medicine:
- Diagnosis and Therapy Decision Support,
- Drug Discovery, Drug Development and Drug Commercialization,
- Value-based Pricing and Reimbursement,
- Overall improvement of healthcare and disease understanding and management at transparent cost and lower prices.
Big Data is not the main challenge. It is data quality, which puts emphasis on curation. Other domains that stand out as success factors: real-time clinical and molecular analytics, AI models customized for biomedicine, and possibly blockchain-like processing structures.
Since 2004, Molecular Health has stood for transforming big data into precise, actionable decisions for all stakeholders in healthcare. The cloud-based MOLECULAR HEALTH DATAOME platform analyzes the molecular and clinical data of individual patients against the world’s medical, biological, and pharmacological knowledge, to drive more precise diagnostic, therapeutic, and drug safety decisions.
Our products are used across the healthcare sector, as more precise ways of practicing medicine impact the treatment of patients and the development of effective drugs, requiring ever more complex levels of data interpretation.
We realize precision medicine.
We realize precision medicine.
Patients are at the center of everything we do.
We want our customers to benefit from the quality of our products and services.
We are committed to continuous improvement and innovation based on health issues and patient needs.
We know it takes people with different ideas, strengths, interests and cultural backgrounds to make our company succeed.
Dievini is an active investor in life and health sciences companies. The company is dedicated to advancing innovative therapeutic and diagnostic technologies to establish novel treatment regimens for life-threatening diseases. Established by Dietmar Hopp, founder and former Chairman and CEO of SAP, the company maintains deep roots in the health and technology sectors and is led by a team with an extensive track record of building scalable, sustainable life science and health technology companies.
Board of directors
Prof. Christof Hettich, PHD
Lawyer and partner at RITTERSHAUS Rehtsanwälte
Mathias Hothum, PHD
Owner of HMM-Consulting
Alexander Schuth, MD
Co-founder and COO of Denali Therapeutics
Dr. Friedrich von Bohlen und Halbach
Chief Executive Officer
Dr. Stephan Brock
Chief Technology Officer
Dr. Rudolf Caspary
Chief Information Officer
Dr. Christian Meisel
Chief Medical Officer
Dr. David Jackson
Chief Innovation Officer
SVP, Global Head of Pharma & Biotech
SVP, Head of Business Development, Sales and Marketing APAC
Dr. Niels Bojunga
SVP Quality Management
Head of HR
Head of Marketing & PR
SVP, Head of Sales & Business Development MH Guide, EMEA
Let’s talk about how our technology can work for you
To find out more, you can call our customer service or send us an e-mail. We would be delighted to provide you with more information or answer your questions.
© 2020 Molecular Health GmbH